First safe syringe in Indian market

By Nick Taylor

- Last updated on GMT

Related tags: Safety syringes, Injection, Marketing

Indian biotech company Biocon has started using pre-filled syringes
for the administration of granulocyte-colony stimulating factor
(GCSF) and erythropoietin.

The use of Safety Syringes' product is the first of its kind in India marks an advance in the adoption of improved, safer delivery methods in the country. Although the Indian pharmaceutical market has grown considerably in recent years this has not been matched by a subsequent rise in sales of safer drug delivery devices. There are signs that this trend is starting to change, with Biocon and Safety Syringes positioning themselves at the forefront of the movement. Speaking to Mark Hassett, executive vice president of Safety Syringes, said the Indian "market will be very big as competitors react​". The initial entry into this market is using Safety Syringes' device for a 1ml long syringe. This system incorporates passive protection, with a safety guard locking into place to prevent sharps injury. Market research conducted by Safety Syringes found that many nurses within the EU want manufacturers to attach the product to their syringes. The company is hoping developing pharmaceutical markets adopt a similar attitude to drive on product sales. India could grow to represent a very significant revenue stream for safe syringe devices, with PricewaterhouseCoopers (PWC) predicting earlier this year that the pharmaceutical market will grow 80 per cent by 2009. Beyond this there is also the Chinese safe syringe market which is yet to ignite but is potentially massive, with PWC believing China will be the biggest pharmaceutical market in the world by 2050. Companies in the safe syringe market will be hoping that as affluence increases and pharmaceutical markets grow across Asia and other developing regions the adoption of safer delivery methods will also occur. Safety Syringes acknowledges it will face competition for these developing markets, for example from BD who also produce a range of safe syringe devices. However, it is Safety Syringes which has acted first in the Indian market through the deal with Biocon. Biocon is using the technology for delivery of GCSF, a hormone which boosts production of white blood cells. This is used to accelerate recovery from neutropenia after chemotherapy, enabling patients to tolerate higher intensity treatments.

Related topics: Drug Delivery, Delivery technologies

Related news

Show more

Related products

Spray Dried Powders for High Dose Drug Delivery

Spray Dried Powders for High Dose Drug Delivery

Catalent | 01-Feb-2022 | Product Presentation

This Catalent webinar will explore how spray dried particles provide an attractive, carrier-free option for highly dispersed delivery of API to deep lung...

Related suppliers

Follow us


View more